Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s HPV Test Approved As First-Line Cervical Cancer Screen

This article was originally published in The Gray Sheet

Executive Summary

The firm’s cobas human papillomavirus test is the first to gain approved labeling as a primary screen. It could be a market advantage for Roche, but the company now needs to work with clinical guideline developers to put the approved indication into routine practice.

You may also be interested in...

Big Week For HPV Dx: FDA Finalizes Guidance, Task Force Supports Solo Testing

An important task force drafted new recommendations supporting human papillomavirus tests as a solo first-line screen for cervical cancer in some women, followed up by a US FDA final guidance document detailing for test-makers how to best ensure assays for the cervical cancer-causing virus are safe and accurate.

Policy Briefs: What's New From FDA And CMS

Updates include an FDA safety communication for the Lariat suture device addressing use for left atrial appendage closure, new FDA draft guidance documents, and CMS proposals to cut radiation therapy payments and launch new payment models for hip and knee replacements.

CMS To Expand Screening Coverage For HIV, HPV

CMS took steps to expand coverage for two infectious diseases: a final decision memo to cover screening for human immunodeficiency virus irrespective of risk and a proposal to cover human papillomavirus screens in combination with Pap smears for women aged 30 to 65.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts